TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07182591: A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS5361b in Participants With Advanced Solid Tumors

Sponsor: Daiichi Sankyo · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 192 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07182591 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07182591 Rescue Dossier →